PubRank

William L Irving

Author PubWeight™ 23.55‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus. Hepatology 2002 2.06
2 Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 2007 1.58
3 IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med 2011 1.36
4 Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. J Gen Virol 2007 1.27
5 Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med 2011 1.19
6 Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. J Virol 2011 1.13
7 A comprehensive study of the association between hepatitis C virus and glomerulopathy. Nephrol Dial Transplant 2002 1.11
8 The natural history of hepatitis C with severe hepatic fibrosis. J Hepatol 2007 1.09
9 Osteopontin is a novel downstream target of SOX9 with diagnostic implications for progression of liver fibrosis in humans. Hepatology 2012 1.09
10 Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype. J Virol 2011 1.07
11 Mannan binding lectin and viral hepatitis. Immunol Lett 2006 1.03
12 Cross-genotype characterization of genetic diversity and molecular adaptation in hepatitis C virus envelope glycoprotein genes. J Gen Virol 2007 0.99
13 Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment. J Clin Epidemiol 2006 0.97
14 Evolutionary trends of the first hypervariable region of the hepatitis C virus E2 protein in individuals with differing liver disease severity. J Gen Virol 2002 0.97
15 Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. Int J Technol Assess Health Care 2009 0.96
16 Evolutionary dynamics of hepatitis C virus envelope genes during chronic infection. J Gen Virol 2005 0.95
17 Act now against new NHS competition regulations: an open letter to the BMA and the Academy of Medical Royal Colleges calls on them to make a joint public statement of opposition to the amended section 75 regulations. BMJ 2013 0.91
18 Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy. Nephrol Dial Transplant 2002 0.85
19 Recombinant human L-ficolin directly neutralizes hepatitis C virus entry. J Innate Immun 2014 0.83
20 Acute hepatitis C virus infection: a dynamic-and challenging-concept. J Infect Dis 2010 0.81
21 Apolipoprotein E and hepatitis C virus. Hepatology 2003 0.77
22 Use of short tandem repeat fingerprinting to validate sample origins in hepatitis C virus molecular epidemiology studies. J Gen Virol 2013 0.75
23 Guidelines on prevention of transmission of hepatitis C virus infection in the workplace: do they work in practice? Occup Med (Lond) 2007 0.75